{
    "title": "Individual feed for https://dealbreaker.com/.rss/full/",
    "link": "https://dealbreaker.com/.rss/full/",
    "description": "Individual feed output.",
    "lastBuildDate": "2025-12-31T06:06:06.957810",
    "items": [
        {
            "title": "European Defense Firm KNDS Targets 2026 For Dual Stock Exchange Listing",
            "link": "https://dealbreaker.com/2025/12/european-defense-firm-knds-targets-2026-for-dual-stock-exchange-listing",
            "description": "The firm, a joint venture between Germany's Krauss-Maffei Wegmann and France's Nexter, amassed an order intake of €11.2 billion ($13.1 billion) in 202...",
            "pubDate": "2025-12-18T18:00:00",
            "image_url": "https://dealbreaker.com/.image/c_fit%2Ch_800%2Cw_1200/MjIwMjQxMjMwNjg3MTE4NDA2/knds.jpg"
        },
        {
            "title": "Anatomy Of A Modern Merger: Finding Long-Term Success",
            "link": "https://dealbreaker.com/2025/12/anatomy-of-a-modern-merger-finding-long-term-success",
            "description": "Our road map for GCs takes you from due diligence to integration.",
            "pubDate": "2025-12-17T18:00:00",
            "image_url": "https://dealbreaker.com/.image/c_fit%2Ch_800%2Cw_1200/MjA0MDQ3NjQyMjIzNzE1OTAw/office-building.jpg"
        },
        {
            "title": "AI Summit 2025: 10 Takeaways And Some Unanswered Questions",
            "link": "https://dealbreaker.com/2025/12/ai-summit-2025-10-takeaways-and-some-unanswered-questions",
            "description": "Right now, our relationship with AI is like one where hard issues are always put off. That never ends well.",
            "pubDate": "2025-12-17T17:00:00",
            "image_url": "https://dealbreaker.com/.image/c_fit%2Ch_800%2Cw_1200/MTYxMjc3Njc4MjExODM1ODY4/robots.png"
        },
        {
            "title": "Mass General Brigham Spins Out Generative AI Startup",
            "link": "https://dealbreaker.com/2025/12/mass-general-brigham-spins-out-generative-ai-startup-",
            "description": "The tool’s primary application is to accelerate and improve the accuracy of patient screening for clinical trials.",
            "pubDate": "2025-12-16T20:00:00",
            "image_url": "https://dealbreaker.com/.image/c_fit%2Ch_800%2Cw_1200/MjIwMjMyMTM5ODUxOTY2MzE3/mass-general-brigham.jpg"
        },
        {
            "title": "Sobi Grows Its Gout Drug Prospects With $950M Acquisition of Startup Arthrosi Therapeutics",
            "link": "https://dealbreaker.com/2025/12/sobi-grows-its-gout-drug-prospects-with-950m-acquisition-of-startup-arthrosi-therapeutics",
            "description": "Arthrosi Therapeutics’ pozdeutinurad is in Phase 3 testing as a treatment for uncontrolled gout.",
            "pubDate": "2025-12-16T19:00:00",
            "image_url": "https://dealbreaker.com/.image/c_fit%2Ch_800%2Cw_1200/MjE3MzM1MTUwODU2MzgxNTc4/pills.jpg"
        }
    ]
}